Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

Vikas, P., Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(9), 649–651. https://doi.org/10.1200/op.22.00284
Authors:
Praveen Vikas
Larissa A. Korde
Mark R. Somerfield
Dawn L. Hershman
Affiliated Authors:
Dawn L. Hershman
Columbia Affiliation:
Subjects:
Cancer Immunotherapy (OpenAlex Topic)
Molecular Research on Breast Cancer (OpenAlex Topic)
Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer (OpenAlex Topic)
Triple Negative Breast Neoplasms (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1200/OP.22.00284
PMID:
35728019
DOI:
10.1200/OP.22.00284
Journal:
JCO Oncology Practice
Publication Date:
Data Source:
Web of Science
Source Link:
View Web of Science Record
View OpenAlex Record

Record Created: